Pharming Reports Q2 2026 Earnings with Mixed Performance Across Product Lines
Pharming Group N.V. reported second-quarter earnings for 2026, showing mixed results across its product lines. Total revenue came in at $90.2 million, a 3% year-over-year decline primarily due to lower sales of RUCONEST. However, sequential growth was observed with a 24% increase compared to Q1 2026 as demand improved. Joenja showed strong performance, generating $17.9 million in revenue—a 40% annual rise—driven by high treatment adherence and new patient starts both domestically and internationally. The company revised its full-year revenue guidance downward to between $375 million and $395 million due to market dynamics affecting hereditary angioedema treatments. Pharming also announced a reduction in operating expenses, attributed to headcount cuts and disciplined spending. Despite these efforts, the firm reported an H1 adjusted operating profit of $10.7 million, down from 2025 due to higher R&D investments.
Tickers: $PHAR
Topics: guidance product_performance revenue